Figure 2.

CTRP9 treatment alleviates cholesterol loading‐induced VSMC pro‐inflammatory factor secretion (A) Cell viability of VSMCs, measured using CCK8, after incubation with CTRP9 for 72 hrs. (B‐D) VSMCs were treated for 72 hrs with different concentrations of CTRP9 (0–10 μg/ml) in the presence of 5 μg/ml cholesterol or were left untreated (control) before measurement of (B) IL‐6 secretion, (C) IL‐1β secretion and (D) MCP‐1 secretion. Values represent the means ± S.D. of triplicate reactions and are representative of three independent experiments. **P < 0.01, ***P < 0.001, ****P < 0.0001.